Skip to main content

Table 3 DPP-4 inhibitors and cardiovascular risk: ongoing studies (adapted from[8])

From: Linagliptin: farmacology, efficacy and safety in type 2 diabetes treatment


TECOS: Trial Evaluating Cardiovascular Outcomes with Sitagliptin


SAVOR: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial


EXAMINE: Examination of Cardiovascular Outcomes: Alogliptin vs Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome


CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes